|
Colorectal Carcinoma
|
0.310 |
Biomarker
|
disease |
BEFREE |
Role of microRNA-30c targeting ADAM19 in colorectal cancer.
|
25799050 |
2015 |
|
Kidney Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
Based on these data, we studied ADAM19 in human nephrogenesis and renal disease.
|
16900093 |
2006 |
|
Kidney Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
To determine whether ADAM19 is specifically related to CAN, we studied transplant biopsies with and without CAN, acute rejection and non-transplant-related kidney diseases: interstitial fibrosis (IF), interstitial atrophy, glomerular fibrosis and interstitial inflammation.
|
16827870 |
2006 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
ADAM19 has been positively associated with numerous diseases, but has not been shown to be a tumor suppressor in the pathogenesis of any human cancers.
|
26912236 |
2016 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
The ADAM8 and ADAM19 proteins were mainly located in tumor cells and in some tumors in endothelia of blood vessels.
|
16772875 |
2006 |
|
ovarian neoplasm
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our previous study showed that ADAM19, a SMAD4 target gene, is downregulated through epigenetic mechanisms in ovarian cancer with aberrant TGF-beta/SMAD4 signaling.
|
20065949 |
2010 |
|
ovarian neoplasm
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer.
|
18714391 |
2008 |
|
Malignant neoplasm of ovary
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our previous study showed that ADAM19, a SMAD4 target gene, is downregulated through epigenetic mechanisms in ovarian cancer with aberrant TGF-beta/SMAD4 signaling.
|
20065949 |
2010 |
|
Malignant neoplasm of ovary
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer.
|
18714391 |
2008 |
|
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
In addition, expression levels and the protease activities of ADAM8 and ADAM19 correlated with invasive activity of glioma cells, indicating that ADAM8 and ADAM19 may play a significant role in tumor invasion that may be detrimental to patients survival.
|
16772875 |
2006 |
|
Tumor Cell Invasion
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
The overexpression of miR-145 could remarkably reduce the expression level of ADAM19 in PC-9/G cells, increase the sensitivity of PC-9/G cells to gefitinib, and inhibit cell invasion and metastasis.
|
31298334 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer.
|
18714391 |
2008 |
|
Carcinoma, Ovarian Epithelial
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our previous study showed that ADAM19, a SMAD4 target gene, is downregulated through epigenetic mechanisms in ovarian cancer with aberrant TGF-beta/SMAD4 signaling.
|
20065949 |
2010 |
|
Alzheimer's Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
ADAM19 is tightly associated with constitutive Alzheimer's disease APP alpha-secretase in A172 cells.
|
17112471 |
2007 |
|
Carcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Based on our investigations and results, we identified ADAM19 as a new biomarker of in vitro and in vivo EMT and we validated this biological new marker in a cohort of non-small lung carcinomas.
|
30814494 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
MiR-145 changes sensitivity of non-small cell lung cancer to gefitinib through targeting ADAM19.
|
31298334 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, we identified that ADAM19 expression was markedly increased in the liver and gonadal white adipose tissue of obese and T2D mice.
|
28265178 |
2017 |
|
Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
MiR-145 inhibits the epithelial-to-mesenchymal transition via targeting ADAM19 in human glioblastoma.
|
29190936 |
2017 |
|
Hemangiosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Angiosarcomas in <i>aP2-Cre;Dicer1<sup>Flox/-</sup></i> mice histologically and genetically resemble human angiosarcoma. miR-23 target genes, including the oncogenes <i>Ccnd1</i> as well as <i>Adam19, Plau</i>, and <i>Wsb1</i> that promote invasiveness and metastasis, were enriched in mouse and human angiosarcoma.
|
28916654 |
2017 |
|
Lymphoma
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Two gene regions (ADAM19 (P=0.009) and ICAM3 (P=0.009)) displayed global associations with lymphoma risk at the P<0.01 level.
|
21239057 |
2011 |
|
Malignant neoplasm of stomach
|
0.010 |
Biomarker
|
disease |
BEFREE |
In both tissue and plasma samples, FLI1 hypermethylation was associated with more advanced GC and liver and distant lymphatic metastasis, and ADAM19 hypermethylation was associated with more stage IV GC.
|
31675985 |
2019 |
|
Neoplasm Metastasis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Meanwhile, it inhibits cell invasion and metastasis through negative regulation on ADAM19.
|
31298334 |
2019 |
|
Obesity
|
0.010 |
Biomarker
|
disease |
BEFREE |
Excitingly, we demonstrate in our diet induced obesity mouse model that neutralising ADAM19 therapy results in weight loss, improves insulin sensitivity, and reduces liver TNF-<i>α</i> levels.
|
28265178 |
2017 |
|
Retinoblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, these findings suggested that miR-145 functions as a tumor suppressor in RB by directly targeting ADAM19. miR-145 could be an anticancer therapeutic target for RB patients.
|
26823772 |
2015 |
|
Polymyositis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we report the expression patterns of ADAM8, ADAM9, ADAM10, ADAM12, ADAM17 and ADAM19 in cultured human myoblasts and peripheral blood mononuclear cells (PBMCs) in vitro, as well as in biopsies from patients suffering from polymyositis (PM), dermatomyositis (DM), inclusion body myositis (IBM) and non-inflammatory controls.
|
17207628 |
2007 |